Relevant bibliographies by topics / ApolipoproteinA-I Milano / Journal articles
To see the other types of publications on this topic, follow the link: ApolipoproteinA-I Milano.

Journal articles on the topic 'ApolipoproteinA-I Milano'

Author: Grafiati
Published: 14 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the top 27 journal articles for your research on the topic 'ApolipoproteinA-I Milano.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.

1

Shah, P. K., J. Nilsson, S. Kaul, et al. "Inhibition of aortic atherosclerosis in apolipoprotein E-deficient mice by recombinant apolipoprotein A-I Milano." Journal of the American College of Cardiology 31 (February 1998): 390. http://dx.doi.org/10.1016/s0735-1097(98)80043-0.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Shah, P. "Inhibition of Aortic Atherosclerosis in Apolipoprotein E-deficient Mice by Recombinant Apolipoprotein A-I Milano." Journal of the American College of Cardiology 31, no. 2 (1998): 390A. http://dx.doi.org/10.1016/s0735-1097(97)85397-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Bhat, Shaila, Mary G. Sorci-Thomas, Laura Calabresi, Michael P. Samuel, and Michael J. Thomas. "Conformation of Dimeric Apolipoprotein A-I Milano on Recombinant Lipoprotein Particles." Biochemistry 49, no. 25 (2010): 5213–24. http://dx.doi.org/10.1021/bi1003734.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Klon, Anthony E., Martin K. Jones, Jere P. Segrest, and Stephen C. Harvey. "Molecular Belt Models for the Apolipoprotein A-I Paris and Milano Mutations." Biophysical Journal 79, no. 3 (2000): 1679–85. http://dx.doi.org/10.1016/s0006-3495(00)76417-4.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Bielicki, John K., Mark R. McCall, Lori J. Stoltzfus, et al. "Evidence That Apolipoprotein A-I Milano Has Reduced Capacity, Compared With Wild-Type Apolipoprotein A-I, to Recruit Membrane Cholesterol." Arteriosclerosis, Thrombosis, and Vascular Biology 17, no. 9 (1997): 1637–43. http://dx.doi.org/10.1161/01.atv.17.9.1637.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Coin, B. D., P. K. Shah, J. Yano, M. D. Molloy, B. Cercek, and S. Kaul. "Reversal of impaired endothelium-dependent vasodilatation in apolipoprotein E-deficient mice by recombinant apolipoprotein A-I Milano." Journal of the American College of Cardiology 31 (1998): 60–61. http://dx.doi.org/10.1016/s0735-1097(98)80909-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Bielicki, J. K., T. M. Forte, M. R. McCall, et al. "High density lipoprotein particle size restriction in apolipoprotein A-I(Milano) transgenic mice." Journal of Lipid Research 38, no. 11 (1997): 2314–21. http://dx.doi.org/10.1016/s0022-2275(20)34945-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Coin, B. D., P. K. Shah, J. Yano, M. D. Molloy, B. Cercek, and S. Kaul. "Recombinant apolipoprotein A-I Millano protects against lysophosphatidylcholine-induced endothelial dysfunction." Journal of the American College of Cardiology 31 (1998): 148. http://dx.doi.org/10.1016/s0735-1097(98)81288-6.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Alexander, Eric T., Masafumi Tanaka, Momoe Kono, Hiroyuki Saito, Daniel J. Rader, and Michael C. Phillips. "Structural and functional consequences of the Milano mutation (R173C) in human apolipoprotein A-I." Journal of Lipid Research 50, no. 7 (2009): 1409–19. http://dx.doi.org/10.1194/jlr.m800578-jlr200.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Ameli, S., A. Hultgardh-Nilsson, B. Cercek, et al. "Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits." Circulation 90, no. 4 (1994): 1935–41. http://dx.doi.org/10.1161/01.cir.90.4.1935.

Full text
APA, Harvard, Vancouver, ISO, and other styles
11

Ma, Cheng-I. J., Jennifer A. Beckstead, Airlia Thompson, et al. "Tweaking the cholesterol efflux capacity of reconstituted HDL." Biochemistry and Cell Biology 90, no. 5 (2012): 636–45. http://dx.doi.org/10.1139/o2012-015.

Full text
Abstract:
Mechanisms to increase plasma high-density lipoprotein (HDL) or to promote egress of cholesterol from cholesterol-loaded cells (e.g., foam cells from atherosclerotic lesions) remain an important target to regress heart disease. Reconstituted HDL (rHDL) serves as a valuable vehicle to promote cellular cholesterol efflux in vitro and in vivo. rHDL were prepared with wild type apolipoprotein (apo) A-I and the rare variant, apoA-I Milano (M), and each apolipoprotein was reconstituted with phosphatidylcholine (PC) or sphingomyelin (SM). The four distinct rHDL generated were incubated with CHO cells
APA, Harvard, Vancouver, ISO, and other styles
12

Bruckert, Eric, Arnold von Eckardstein, Harald Funke, et al. "The replacement of arginine by cysteine at residue 151 in Apolipoprotein A-I produces a phenotype similar to that of Apolipoprotein A-I Milano." Atherosclerosis 128, no. 1 (1997): 121–28. http://dx.doi.org/10.1016/s0021-9150(96)05982-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
13

Wang, Lai, Behrooz G. Sharifi, Theresa Pan, Lei Song, Ada Yukht, and Prediman K. Shah. "Bone Marrow Transplantation Shows Superior Atheroprotective Effects of Gene Therapy With Apolipoprotein A-I Milano Compared With Wild-Type Apolipoprotein A-I in Hyperlipidemic Mice." Journal of the American College of Cardiology 48, no. 7 (2006): 1459–68. http://dx.doi.org/10.1016/j.jacc.2006.07.040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
14

Nicholls, Stephen J., E. Murat Tuzcu, Ilke Sipahi, et al. "Relationship Between Atheroma Regression and Change in Lumen Size After Infusion of Apolipoprotein A-I Milano." Journal of the American College of Cardiology 47, no. 5 (2006): 992–97. http://dx.doi.org/10.1016/j.jacc.2005.11.040.

Full text
APA, Harvard, Vancouver, ISO, and other styles
15

Cimmino, Giovanni, Walter S. Speidl, Sammy Elmariah, et al. "RECOMBINANT APOLIPOPROTEIN A-I MILANO DECREASES LEAFLET INFLAMMATION AND CALCIFICATION IN EXPERIMENTAL MODELS OF AORTIC STENOSIS." Journal of the American College of Cardiology 55, no. 10 (2010): A152.E1426. http://dx.doi.org/10.1016/s0735-1097(10)61427-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
16

Rocco, Alessandro Guerini, Cristina Sensi, Elisabetta Gianazza, et al. "Structural and dynamic features of apolipoprotein A-I cysteine mutants, Milano and Paris, in synthetic HDL." Journal of Molecular Graphics and Modelling 29, no. 3 (2010): 406–14. http://dx.doi.org/10.1016/j.jmgm.2010.08.002.

Full text
APA, Harvard, Vancouver, ISO, and other styles
17

Bekaert, ED, P. Alaupovic, CS Knight-Gibson, G. Franceschini, and CR Sirtori. "Apolipoprotein A-I Milano: sex-related differences in the concentration and composition of apoA-I- and apoB-containing lipoprotein particles." Journal of Lipid Research 34, no. 1 (1993): 111–23. http://dx.doi.org/10.1016/s0022-2275(20)41325-2.

Full text
APA, Harvard, Vancouver, ISO, and other styles
18

Guerini Rocco, A., L. Mollica, E. Gianazza, L. Calabresi, C. R. Sirtori, and I. Eberini. "Tu-W16:8 A structural model for apolipoprotein A-I Milano (A-IM) in its heterodimeric form with apolipoprotein A-II (A-II)." Atherosclerosis Supplements 7, no. 3 (2006): 154. http://dx.doi.org/10.1016/s1567-5688(06)80604-5.

Full text
APA, Harvard, Vancouver, ISO, and other styles
19

Speidl, W. S., G. Cimmino, B. Ibanez, et al. "Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model." European Heart Journal 31, no. 16 (2010): 2049–57. http://dx.doi.org/10.1093/eurheartj/ehq064.

Full text
APA, Harvard, Vancouver, ISO, and other styles
20

Nicholls, Stephen J., Rishi Puri, Christie M. Ballantyne, et al. "Effect of Infusion of High-Density Lipoprotein Mimetic Containing Recombinant Apolipoprotein A-I Milano on Coronary Disease in Patients With an Acute Coronary Syndrome in the MILANO-PILOT Trial." JAMA Cardiology 3, no. 9 (2018): 806. http://dx.doi.org/10.1001/jamacardio.2018.2112.

Full text
APA, Harvard, Vancouver, ISO, and other styles
21

Kaul, Sanjay, Vladimir Rukshin, Raul Santos, et al. "Intramural Delivery of Recombinant Apolipoprotein A-I Milano /Phospholipid Complex (ETC-216) Inhibits In-Stent Stenosis in Porcine Coronary Arteries." Circulation 107, no. 20 (2003): 2551–54. http://dx.doi.org/10.1161/01.cir.0000074042.19447.b1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
22

Gomaraschi, Monica, Damiano Baldassarre, Mauro Amato, et al. "Normal Vascular Function Despite Low Levels of High-Density Lipoprotein Cholesterol in Carriers of the Apolipoprotein A-I Milano Mutant." Circulation 116, no. 19 (2007): 2165–72. http://dx.doi.org/10.1161/circulationaha.107.705657.

Full text
APA, Harvard, Vancouver, ISO, and other styles
23

Chetty, Palaniappan Sevugan, Maki Ohshiro, Hiroyuki Saito, et al. "Effects of the Iowa and Milano Mutations on Apolipoprotein A-I Structure and Dynamics Determined by Hydrogen Exchange and Mass Spectrometry." Biochemistry 51, no. 44 (2012): 8993–9001. http://dx.doi.org/10.1021/bi300926j.

Full text
APA, Harvard, Vancouver, ISO, and other styles
24

Yan, Ying, Shulai Lu, Shaoyou Jia, Qingzhe Dong, Lei Wang, and Yunlong Wang. "Function of different proportions of apolipoprotein A-I cysteine mutants and apolipoprotein A-V on recombinant high-density lipoproteins in vitro." Bioscience Reports 39, no. 5 (2019). http://dx.doi.org/10.1042/bsr20190547.

Full text
Abstract:
Abstract To explore the anti-atherosclerotic effects of recombinant high-density lipoproteins (rHDL) of apolipoprotein AI wild-type (apoA-Iwt), apolipoprotein AI Milano (apoA-IM), apolipoprotein AI (N74C) (apoA-I (N74C) )and apolipoprotein AV (apoA-V). We constructed rHDL liposomes (rHDLs), which included apoA-Iwt, apoA-IM, and apoA-I (N74C), followed by the synthesis of rHDLs, with the indicated ratios of apoA-Iwt, apoA-IM, apoA-I (N74C) and apoA-V. We investigated the anti-atherosclerotic effects by experiments including the DMPC clearance assay and experiments that assessed the in vitro ant
APA, Harvard, Vancouver, ISO, and other styles
25

Kalayci, Arzu, C. Michael Gibson, Paul M. Ridker, et al. "ApoA-I Infusion Therapies Following Acute Coronary Syndrome: Past, Present, and Future." Current Atherosclerosis Reports, May 7, 2022. http://dx.doi.org/10.1007/s11883-022-01025-7.

Full text
Abstract:
Abstract Purpose of Review The elevated adverse cardiovascular event rate among patients with low high-density lipoprotein cholesterol (HDL-C) formed the basis for the hypothesis that elevating HDL-C would reduce those events. Attempts to raise endogenous HDL-C levels, however, have consistently failed to show improvements in cardiovascular outcomes. However, steady-state HDL-C concentration does not reflect the function of this complex family of particles. Indeed, HDL functions correlate only weakly with serum HDL-C concentration. Thus, the field has pivoted from simply raising the quantity o
APA, Harvard, Vancouver, ISO, and other styles
26

Bellibas, S. Eralp, David Kallend, Alain Bobillier, Herman Kempen, and Peter L. Wijngaard. "Abstract 13324: Single Ascending Dose Pharmacokinetics and Pharmacodynamics of MDCO-216 (ApoA-I Milano/POPC) in Healthy Volunteers." Circulation 130, suppl_2 (2014). http://dx.doi.org/10.1161/circ.130.suppl_2.13324.

Full text
Abstract:
Introduction: MDCO-216, a complex of dimeric recombinant apolipoprotein A-I Milano (apoA-I M) and a phospholipid (POPC), is currently under development to improve cardiovascular outcomes by reducing plaque burden in patients with atherosclerotic disease. An earlier version of MDCO-216 has been shown to reduce atherosclerotic plaque burden in animal models and in patients with ACS. The purpose of this study was to assess the pharmacokinetics (PK), pharmacodynamics (PD), safety and tolerability of newly manufactured MDCO-216 first time in healthy volunteers. Methods: 24 healthy volunteers receiv
APA, Harvard, Vancouver, ISO, and other styles
27

Bellibas, S. Eralp, David Kallend, Alain Bobillier, Herman Kempen, and Peter L. Wijngaard. "Abstract 13357: MDCO-216 (ApoA-I Milano/POPC) Induces Reverse Cholesterol Transport in Stable Coronary Artery Disease Patients with a Dose Proportional Pharmacokinetics after Single Ascending Doses." Circulation 130, suppl_2 (2014). http://dx.doi.org/10.1161/circ.130.suppl_2.13357.

Full text
Abstract:
Introduction: MDCO-216, a complex of dimeric recombinant apolipoprotein A-I Milano (apoA-I M) and a phospholipid (POPC), is currently under development to improve cardiovascular outcomes by reducing plaque burden in patients with atherosclerotic disease. An earlier version of MDCO-216 has been shown effective in animal models and in patients with ACS. The purpose of this study was to assess the pharmacokinetics (PK), pharmacodynamics (PD) and safety of MDCO-216, manufactured by an improved process, first time in stable coronary artery disease (CAD) patients. Methods: 24 patients with known sta
APA, Harvard, Vancouver, ISO, and other styles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography